Activity of Blinatumomab in NHL and ALL Highlighted at the 14th Congress of the European Hematology Association (EHA)
Adecatumumab Combination Data in Breast Cancer to Be Presented at the American Society of Clinical Oncology (ASCO) Meeting
BETHESDA, Md., May 20 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced an oral(1) and a poster presentation(2) of blinatumomab data at the 14th Congress of European Hematology Association (EHA) taking place from June 4-7, 2009, in Berlin, Germany. Interim data from the phase 2 clinical trial with blinatumomab in patients with acute lymphoblastic leukemia (ALL) were chosen for an oral presentation, while an update from the phase 1 trial with blinatumomab in patients with non-Hodgkin's lymphoma (NHL) will be presented in a poster and include additional data on the durability of responses last presented at the American Society of Hematology meeting in December 2008 and efficacy data from additional patients.
Micromet also announced a poster presentation(3) for adecatumumab at the 45th annual meeting of ASCO taking place from May 29 - June 2 in Orlando, Florida. The new data will include an update of the data presented at the European Society of Oncology (ESMO) meeting in October of 2008.
(1) Topp et al, (2009) Blinatumomab (anti-CD19 BiTE(R)) for targeted therapy of minimal residual disease (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing phase II study. 14th Congress of EHA (2009), abstract number 482; oral presentation on June 6 in Hall 15.2 at 8:15 AM.
(2) Klinger, et al. (2009) Pharmacodynamic analyses of peripheral blood from relapsed B-NHL pat
|SOURCE Micromet, Inc.|
Copyright©2009 PR Newswire.
All rights reserved